NanoViricides confirmed in a statement that its CEO, Dr. Irach Taraporewala has resigned effective January 31, 2019, for personal reasons, and will continue as a Consultant to help the company with its regulatory advance as needed. The Board has promoted current President and Board Chairman, Dr. Anil Diwan, to Executive Chairman.
NanoViricides got its first drug candidate in IND-enabling Safety/Toxicology studies moving towards human clinical trials, as the first part of the IND-enabling Safety/Toxicology studies for the shingles drug candidate began towards the end of December, 2018.
The company said it has chosen the candidate now called NV-HHV-101 as the clinical drug candidate based on these drug candidate optimization studies.
By Dino Mustafić